205 related articles for article (PubMed ID: 29374194)
21. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
22. Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.
Nathubhai A; Haikarainen T; Koivunen J; Murthy S; Koumanov F; Lloyd MD; Holman GD; Pihlajaniemi T; Tosh D; Lehtiö L; Threadgill MD
J Med Chem; 2017 Jan; 60(2):814-820. PubMed ID: 27983846
[TBL] [Abstract][Full Text] [Related]
23. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
[TBL] [Abstract][Full Text] [Related]
24. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
25. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.
Xu W; Lau YH; Fischer G; Tan YS; Chattopadhyay A; de la Roche M; Hyvönen M; Verma C; Spring DR; Itzhaki LS
J Am Chem Soc; 2017 Feb; 139(6):2245-2256. PubMed ID: 28084734
[TBL] [Abstract][Full Text] [Related]
26. The zinc-binding motif in tankyrases is required for the structural integrity of the catalytic ADP-ribosyltransferase domain.
Sowa ST; Lehtiö L
Open Biol; 2022 Mar; 12(3):210365. PubMed ID: 35317661
[TBL] [Abstract][Full Text] [Related]
27. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
Mariotti L; Templeton CM; Ranes M; Paracuellos P; Cronin N; Beuron F; Morris E; Guettler S
Mol Cell; 2016 Aug; 63(3):498-513. PubMed ID: 27494558
[TBL] [Abstract][Full Text] [Related]
28. Tankyrases maintain homeostasis of intestinal epithelium by preventing cell death.
Ye P; Chiang YJ; Qi Z; Li Y; Wang S; Liu Y; Li X; Chen YG
PLoS Genet; 2018 Sep; 14(9):e1007697. PubMed ID: 30260955
[TBL] [Abstract][Full Text] [Related]
29. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
[TBL] [Abstract][Full Text] [Related]
30. Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy.
Li X; Han H; Zhou MT; Yang B; Ta AP; Li N; Chen J; Wang W
Cell Rep; 2017 Jul; 20(3):737-749. PubMed ID: 28723574
[TBL] [Abstract][Full Text] [Related]
31. Tankyrases: structure, function and therapeutic implications in cancer.
Haikarainen T; Krauss S; Lehtio L
Curr Pharm Des; 2014; 20(41):6472-88. PubMed ID: 24975604
[TBL] [Abstract][Full Text] [Related]
32. Tankyrase-1 Ankyrin Repeats Form an Adaptable Binding Platform for Targets of ADP-Ribose Modification.
Eisemann T; McCauley M; Langelier MF; Gupta K; Roy S; Van Duyne GD; Pascal JM
Structure; 2016 Oct; 24(10):1679-1692. PubMed ID: 27594684
[TBL] [Abstract][Full Text] [Related]
33. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
34. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y
Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184
[TBL] [Abstract][Full Text] [Related]
36.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
37. Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro.
Paine HA; Nathubhai A; Woon EC; Sunderland PT; Wood PJ; Mahon MF; Lloyd MD; Thompson AS; Haikarainen T; Narwal M; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Sep; 23(17):5891-908. PubMed ID: 26189030
[TBL] [Abstract][Full Text] [Related]
38. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
Yakkala PA; Naaz F; Shafi S; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
[TBL] [Abstract][Full Text] [Related]
39. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
40. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
